<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080028</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0210</org_study_id>
    <nct_id>NCT00080028</nct_id>
  </id_info>
  <brief_title>Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of adding the investigational drug
      Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with
      drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>18</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Larynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin Gadolinium Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Each patient must sign a study-specific informed consent form

          -  Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head
             and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or larynx
             confirmed by evaluation of fine needle aspiration or biopsy samples and MRI

          -  Eligible for curative intent treatment with hyperfractionated radiation and concurrent
             5-FU and cisplatin

          -  Karnofsky Performance Status score of at least 60%

          -  Primary tumor at least 4 cm in diameter

        Exclusion Criteria:

        Laboratory Values of:

          -  Serum creatinine &gt; 1.8 mg/dL; unless 24-hour urine creatinine clearance is â‰¥ 70 mL/min

          -  Serum total bilirubin &gt; 1.5 times the upper limit of normal

          -  ALT (formerly SGPT) &gt; 1.5 times the upper limit of normal

          -  Alkaline phosphatase &gt; 1.5 times the upper limit of normal

          -  Absolute neutrophil count (ANC) &lt; 1500/L

          -  Platelet count &lt; 100,000/L

          -  3+ or greater proteinuria on urinalysis

        and

          -  Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral
             cavity or nasopharynx

          -  Distant metastases

          -  Prior history of cancer at any site treated with radiotherapy and/or chemotherapy

          -  History of SCCHN diagnosed within 5 years of current diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, San Antonio Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2004</study_first_submitted>
  <study_first_submitted_qc>March 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2004</study_first_posted>
  <last_update_submitted>May 4, 2007</last_update_submitted>
  <last_update_submitted_qc>May 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2007</last_update_posted>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Oropharynx Cancer</keyword>
  <keyword>Hypopharynx Cancer</keyword>
  <keyword>Larynx Cancer</keyword>
  <keyword>Soft palate Cancer</keyword>
  <keyword>Tonsil Cancer</keyword>
  <keyword>Base of tongue Cancer</keyword>
  <keyword>Supraglottic Cancer</keyword>
  <keyword>Glottic Cancer</keyword>
  <keyword>Pyriform Sinus Cancer</keyword>
  <keyword>Pharyngeal wall Cancer</keyword>
  <keyword>Throat cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

